We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
AstraZeneca and Daiichi Sankyo announced Wednesday that a pivotal Phase II study of trastuzumab deruxtecan in patients with refractory HER2-positive metastatic breast cancer met its primary endpoint ...